SD Global

Growth hormone (GH) 191AA, also known as somatotropin, is a naturally occurring hormone produced by the pituitary gland. It consists of a chain of 191 amino acids and plays a crucial role in growth, development, and metabolism in the human body.

GH 191AA regulates various physiological processes, including stimulating linear growth in children and adolescents, promoting protein synthesis, increasing bone mineral density, and regulating metabolism of fats, carbohydrates, and proteins. It also has indirect effects on body composition, muscle growth, and tissue repair.

GH 191AA deficiencies can lead to growth disorders, such as dwarfism in children, and may cause metabolic disturbances. In some cases, individuals may receive exogenous GH 191AA as a therapeutic intervention to address growth hormone deficiencies or medical conditions associated with its insufficiency.

It’s worth noting that the use of GH 191AA or any form of growth hormone for non-medical purposes, such as athletic performance enhancement or anti-aging treatments, is considered controversial and may have potential risks and side effects. Therefore, such use should only be undertaken under the guidance and supervision of a qualified healthcare professional.

Soma Max 10 is an injectable product that is often used by bodybuilders in a steroid cycle. The active substance of this medication is Human Growth Hormone. Original Soma Max 10 is produced by the world famous brand Maxtreme Pharma. Packing of this product includes 10 vials (10 IU/vial).

Professional athletes prefer Soma Max 10 for its effective properties. Individual dosage and duration of admission is prescribed by a specialist. To avoid side effects of anabolic steroids is recommended to use Post Cycle Therapy (PCT).

As a rule, with the proper use of this product from Maxtreme Pharma, negative phenomena do not occur. But its important to remember that before you start using Soma Max 10, you should consult your doctor.

In the HGH injection section you can see products from other manufacturers. We also recommend that you familiarize the full section of Human Growth Hormone.

Recombinant Human Growth Hormone Somatropin(rDNA origin) for Injection

100IU kit 10 Vials x 10 RJ

Genryzon (Somatrogon), is a medication for the treatment of growth hormone deficiency. Somatrogon is a glycosylated protein constructed from human growth hormone and a small part of human chorionic gonadotropin which is appended to both the N-terminal and C-terminal.

Genryzon (somatrogon) is a synthetic growth hormone that works by replacing the lack of growth hormone in the body. Genryzon is taken by injection just below the skin. Compared to the growth hormone GENOTROPIN^® (somatropin), its action in the body lasts longer, enabling weekly injections instead of daily. Genryzon is approved for the treatment of pediatric growth hormone deficiency (GHD) in Canada, Australia and Japan, and the EU marketing authorization is valid in all EU Member States as well as Iceland, Norway and Liechtenstein.

The next-generation long-acting recombinant human growth hormone somatrogon, is a once-weekly injection to treat children and adolescents from 3 years of age with growth disturbance due to insufficient secretion of growth hormone. Genryzon provides pediatric patients, their caregivers and healthcare providers with a new treatment option for growth hormone deficiency (GHD) that reduces the frequency of required injections from once daily to once weekly.

GHD is a rare disease characterized by the inadequate secretion of the growth hormone, somatropin, from the pituitary gland and affects one in approximately 4,000 to 10,000 children worldwide. The disease can be caused by genetic mutations or acquired after birth. Without treatment, affected children will have persistent growth attenuation and a very short height in adulthood, and puberty may be delayed.Children may also experience other problems with physical health and mental well-being.

The safety and efficacy of Genryzon (somatrogon) was demonstrated in a randomized, open-label, active-controlled Phase 3 study conducted in over 20 countries. In this study, 224 prepubertal, treatment-naïve children with growth hormone deficiency (GHD) were randomized 1:1 to receive NGENLA once-weekly or GENOTROPIN^® (somatropin) once-daily. The study met its primary endpoint of Genryzon non-inferiority compared to GENOTROPIN, as measured by annual height velocity at 12 months. Genryzon was generally well tolerated in the study and had a safety profile comparable to GENOTROPIN. Participants had the opportunity to enroll in a global, open-label, multicenter, long-term extension study in which they were able to either continue receiving or switch to Genryzon. Approximately 95% of the patients switched into the open-label extension study and received Genryzon treatment.

Genryzon (Somatrogon), is a medication for the treatment of growth hormone deficiency. Somatrogon is a glycosylated protein constructed from human growth hormone and a small part of human chorionic gonadotropin which is appended to both the N-terminal and C-terminal.

Genryzon (somatrogon) is a synthetic growth hormone that works by replacing the lack of growth hormone in the body. Genryzon is taken by injection just below the skin. Compared to the growth hormone GENOTROPIN^® (somatropin), its action in the body lasts longer, enabling weekly injections instead of daily. Genryzon is approved for the treatment of pediatric growth hormone deficiency (GHD) in Canada, Australia and Japan, and the EU marketing authorization is valid in all EU Member States as well as Iceland, Norway and Liechtenstein.

The next-generation long-acting recombinant human growth hormone somatrogon, is a once-weekly injection to treat children and adolescents from 3 years of age with growth disturbance due to insufficient secretion of growth hormone. Genryzon provides pediatric patients, their caregivers and healthcare providers with a new treatment option for growth hormone deficiency (GHD) that reduces the frequency of required injections from once daily to once weekly.

GHD is a rare disease characterized by the inadequate secretion of the growth hormone, somatropin, from the pituitary gland and affects one in approximately 4,000 to 10,000 children worldwide. The disease can be caused by genetic mutations or acquired after birth. Without treatment, affected children will have persistent growth attenuation and a very short height in adulthood, and puberty may be delayed.Children may also experience other problems with physical health and mental well-being.

The safety and efficacy of Genryzon (somatrogon) was demonstrated in a randomized, open-label, active-controlled Phase 3 study conducted in over 20 countries. In this study, 224 prepubertal, treatment-naïve children with growth hormone deficiency (GHD) were randomized 1:1 to receive NGENLA once-weekly or GENOTROPIN^® (somatropin) once-daily. The study met its primary endpoint of Genryzon non-inferiority compared to GENOTROPIN, as measured by annual height velocity at 12 months. Genryzon was generally well tolerated in the study and had a safety profile comparable to GENOTROPIN. Participants had the opportunity to enroll in a global, open-label, multicenter, long-term extension study in which they were able to either continue receiving or switch to Genryzon. Approximately 95% of the patients switched into the open-label extension study and received Genryzon treatment.

Igtropure (IGF-1LR3) is a synthetic form of Insulin-Like Growth Factor 1 (IGF-1), modified by a substitution of the arginine at position 3 with leucine (hence the LR3). This modification extends the half-life of the peptide and increases its potency, making it a popular compound in research and sometimes bodybuilding.

Here’s some basic information about Igtropure (IGF-1LR3):

1. What is IGF-1LR3? IGF-1LR3 is a modified version of IGF-1, a naturally occurring protein in the body that promotes cell growth and development. The modification at the third position (from arginine to leucine) enhances its binding affinity to IGF receptors and delays its degradation, allowing for prolonged activity.
2. Uses and Benefits:
   • Growth and Repair: IGF-1LR3 is believed to stimulate muscle growth, increase the number of muscle cells, and aid in faster recovery after physical exertion or injury.
   • Anti-aging Effects: Some studies suggest it can have anti-aging effects by promoting cell regeneration and improving skin elasticity.
   • Fat Loss: By improving metabolism, it might help with fat loss, although its effectiveness for this purpose is still debated.
3. Administration: IGF-1LR3 is typically administered through subcutaneous injection, often in the same way as insulin. It’s generally used in short bursts of therapy.
4. Side Effects:
   • Hypoglycemia: Since it can increase insulin sensitivity, improper use might cause low blood sugar.
   • Joint Pain: Some users report discomfort in their joints.
   • Acromegaly-like symptoms: Overuse may potentially cause abnormal growth of bones and tissues.

Recombinant Insulin-like Growth Factor 1 Long R3 (IGF-1-LR3) is a modified form of insulin-like growth factor 1 (IGF-1), a naturally occurring peptide hormone involved in cell growth and repair. IGF-1-LR3 is created by altering the structure of the IGF-1 molecule to increase its biological activity and prolong its half-life in the body.

Here are some key points about recombinant IGF-1-LR3:

1. Increased Potency: The modification of IGF-1 to create IGF-1-LR3 results in a peptide with increased potency and bioavailability compared to natural IGF-1. It has a longer half-life in the body, which means it remains active for an extended period, leading to enhanced effects.
2. Insulin-Like Effects: IGF-1-LR3 binds to the insulin-like growth factor receptors (IGF-1R) in the body, promoting cell growth, division, and proliferation. It exhibits similar effects to insulin in terms of its ability to regulate glucose metabolism and transport.
3. Muscle Growth and Repair: IGF-1-LR3 is known for its anabolic properties and its ability to stimulate muscle growth and repair. It promotes protein synthesis and helps to increase muscle mass, strength, and endurance.
4. Fat Loss: IGF-1-LR3 also has the potential to aid in fat loss. It can enhance lipolysis (the breakdown of fat) and inhibit lipogenesis (the synthesis of fat), resulting in reduced body fat levels.
5. Recovery and Injury Healing: Due to its role in cell growth and repair, IGF-1-LR3 is sometimes used to aid in the recovery from injuries, such as muscle strains or ligament damage. It may help accelerate the healing process and improve tissue regeneration.

The HGH fragment (176-191) is a synthetic peptide that represents a specific short portion of the amino acid chain found in HGH. This fragment corresponds to amino acids located at positions 176-191 at the C-terminus of the human growth hormone. While only a fraction of the full HGH molecule, this fragment is responsible for its potent fat burning properties without significantly affecting insulin levels.

Clinical trials, conducted on both humans and animals, have confirmed that the HGH fragment leads to the breakdown of fat (lipolysis) and inhibits the formation of new fat cells (lipogenesis). In fact, the fat-burning effect of the HGH fragment can be up to 12.5 times more potent than that of HGH itself. By mimicking the natural regulation of fat breakdown by human growth hormone, the HGH fragment 176-191 offers these benefits without the unwanted side effects on blood sugar, insulin levels, or cell proliferation.

Recombinant Insulin-like Growth Factor 1 Long R3 (IGF-1-LR3) is a modified form of insulin-like growth factor 1 (IGF-1), a naturally occurring peptide hormone involved in cell growth and repair. IGF-1-LR3 is created by altering the structure of the IGF-1 molecule to increase its biological activity and prolong its half-life in the body.

Here are some key points about recombinant IGF-1-LR3:

1. Increased Potency: The modification of IGF-1 to create IGF-1-LR3 results in a peptide with increased potency and bioavailability compared to natural IGF-1. It has a longer half-life in the body, which means it remains active for an extended period, leading to enhanced effects.
2. Insulin-Like Effects: IGF-1-LR3 binds to the insulin-like growth factor receptors (IGF-1R) in the body, promoting cell growth, division, and proliferation. It exhibits similar effects to insulin in terms of its ability to regulate glucose metabolism and transport.
3. Muscle Growth and Repair: IGF-1-LR3 is known for its anabolic properties and its ability to stimulate muscle growth and repair. It promotes protein synthesis and helps to increase muscle mass, strength, and endurance.
4. Fat Loss: IGF-1-LR3 also has the potential to aid in fat loss. It can enhance lipolysis (the breakdown of fat) and inhibit lipogenesis (the synthesis of fat), resulting in reduced body fat levels.
5. Recovery and Injury Healing: Due to its role in cell growth and repair, IGF-1-LR3 is sometimes used to aid in the recovery from injuries, such as muscle strains or ligament damage. It may help accelerate the healing process and improve tissue regeneration.